Tuesday 6th June 2023 |
Text too small? |
The a2 Milk Company (a2MC, the Company) notes the announcement from Synlait Milk (Synlait) today confirming it has received approval from China’s State Administration for Market Regulation (SAMR) for the re-registration of a2MC’s China label infant milk formula (IMF) product, 至初® (stages 1, 2 and 3), formulated in line with China’snew GB standards.
SAMR’s approval will allow Synlait to manufacture 至初® for a2MC until September 20271. Production is expected to commence later this month with product transitioning in market during 1H242.
The a2 Milk Company’s Managing Director and CEO, David Bortolussi said:
• “We are pleased to confirm that our China label IMF product re-registration has been approved.
• “We extend our sincere thanks to China’s State Administration for Market Regulation, New Zealand’s Ministry for Primary Industries, our strategic partners in China, CNADC Group and China State Farm Agribusiness, and our manufacturing partner, Synlait and its major shareholder Bright Dairy, for their support throughout the process.
• “We look forward to making our upgraded new China label IMF product available to parents and their infants and young children in China, building on the strong brand loyalty we have developed with Chinese families over the past decade as the pioneer and leader of the A2 protein category.
• “The approval provides a2MC with continued access to China's substantial registered domestic infant milk formula market which remains the key focus of our refreshed growth strategy.”
No comments yet
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report